Radiopharma developers Actithera, Nuclidium draw venture cash: Finance Report

VC syndicates have backed a pair of companies that hope to address challenges in the fast-growing  radiopharma arena, as Actithera raised $75.5 million in its series A and Nuclidium closed its series B with CHF79 million ($99.5 million).

Actithera Inc., based in Cambridge, Mass., and Oslo, believes its approach using covalent targeting and optimized vectors can prolong tumor residence time, thus conferring safety and efficacy benefits. The company will test its thesis via development of a radioligand therapy targeting the popular next-wave radiopharma target FAP; the company said it has an “isotope-agnostic” strategy...